Business Context and Reporting Period
This Form 8-K Current Report, dated October 25, 2002, covers the completion of a merger by Harvard Bioscience, Inc. (the "Company"). The report details the acquisition of Genomic Solutions Inc., a Delaware corporation, effective October 25, 2002. The transaction was executed by merging Genomic Solutions into HAG Acq. Corp., a wholly-owned subsidiary of the Company, which was subsequently renamed Genomic Solutions Inc.
Key Financial Metrics and Transaction Details
The filing does not provide specific revenue, profit, cash flow, margin, or debt figures for the Company or the acquired entity within this document. Financial statements and pro forma information were previously reported in the Company's Registration Statement on Form S-4 (File No. 333-98927) and are incorporated by reference.
Key transaction metrics include:
- Purchase Price: Approximately 3,200,000 shares of the Company's common stock and approximately $9,000,000 in cash.
- Funding Source: The cash portion was funded using the Company's general working capital.
- Accounting Treatment: The merger is accounted for as a purchase transaction.
Material Changes
The primary material change is the expansion of the Company's asset base and operations through the acquisition of Genomic Solutions. Genomic Solutions develops, manufactures, and sells instruments, consumables, and software for life sciences research and drug discovery markets. The Company intends to continue utilizing these assets for the same purposes. Additionally, Jeffrey S. Williams, former President and CEO of Genomic Solutions, was appointed to the Board of Directors of Harvard Bioscience, Inc., effective October 28, 2002.
Guidance, Outlook, and Risks
The filing contains forward-looking statements regarding the anticipated results and performance of the combined entity. The Company explicitly disclaims any obligation to update these statements. It warns that actual results may differ materially due to known and unknown risks and uncertainties. Specific risk factors are referenced in the "Important Factors That May Affect Future Operating Results" section of the Company's Annual Report on Form 10-K for the year ended December 31, 2001. No specific financial guidance or outlook numbers are provided in this text.
Investor Verification Checklist
- Review the Registration Statement on Form S-4 (File No. 333-98927) for the audited financial statements of Genomic Solutions and the unaudited pro forma combined financial information.
- Verify the impact of the $9,000,000 cash outlay on the Company's current liquidity and working capital position.
- Examine the Form 10-K for the year ended December 31, 2001, to understand the specific risk factors cited in this report.
- Confirm the valuation of the 3,200,000 shares issued based on the stock price at the time of the merger.